Publisher
Springer International Publishing
Reference74 articles.
1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Prevymis FDA Application Multi-Discipline Review, Nov 8, 2017. Retrieved July 1, 2024, from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000SumR.pdf
2. Prevymis [package insert]. Whitehouse Station, NJ: Merck; 2017.
3. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. New England Journal of Medicine. 2017;377(25):2433–2444.
4. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54(3):1290–1297.
5. Hakki M. Moving past ganciclovir and foscarnet: advances in cmv therapy. Curr Hematol Malig Rep. 2020;15(2):90–102.